ACET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Adicet Bio Inc (ACET) is not a strong buy for a beginner investor with a long-term focus at this time. While the stock shows potential upside based on analyst ratings and price targets, the lack of recent positive news, neutral trading sentiment, and bearish technical indicators suggest waiting for more clarity or stronger signals before investing.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 57.984, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 8.204), with limited immediate upside potential.
Analysts have a Buy rating on the stock with significant upside potential in price targets ($19 and $27). The company's off-the-shelf allogeneic CD20 CAR-T therapy shows encouraging safety and efficacy data.
The stock is trading at a negative enterprise value, reflecting investor skepticism around its pipeline. There is no recent news or significant trading activity from insiders, hedge funds, or Congress to indicate strong interest. Technical indicators are not strongly supportive of a buy.
No financial data is available for analysis.
Jefferies initiated coverage with a Buy rating and a price target of $19, citing encouraging early Phase I data. H.C. Wainwright lowered its price target from $50 to $27 due to higher long-term operating expenses but maintained a Buy rating.
